Jump to content

Russia to sell 100 million doses of Covid-19 vaccine ‘Sputnik V’ to India: Report

Kool_SRG

By Kool_SRG
in Discussions

 Share

Recommended Posts

Kool_SRG VIP

Kool_SRG

Posted
Posted

Russia’s sovereign wealth fund has agreed a deal to sell 100 million doses of its Covid-19 vaccine, Sputnik-V, to a major listed pharmaceutical company in India, a source close to the deal said on Wednesday.

Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said.

Russia’s sovereign wealth fund has agreed a deal to sell 100 million doses of its Covid-19 vaccine, Sputnik-V, to a major listed pharmaceutical company in India, a source close to the deal said on Wednesday.

Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said. Both the trials and supply deal depend on domestic regulatory approval.

The Russian Direct Investment Fund (RDIF) has already inked vaccine supply deals with Kazakhstan, Brazil and Mexico and has reached a manufacturing partnership agreement with India to produce 300 million doses of the Sputnik-V vaccine there.

RDIF will announce the name of the Indian firm later on Wednesday, the source said.

Russia has billed Sputnik-V as the first vaccine against corona virus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on Aug. 26 but have yet to be completed.

Link to comment
Share on other sites
Kool_SRG VIP

Kool_SRG

Posted
  • Author
Posted

Dr. Reddy's Lab Ties up with Russia for Phase-III Trials of Sputnik V Vaccine, to Procure 10 Crore Doses

The development comes a week after the government confirmed it was in talks with the Russians for production of the vaccine in India and conducting Phase-III clinical trials of the same.

 

Indian pharma giant Dr. Reddy’s Laboratory Ltd. has partnered with the Russian Direct Investment Fund (RDIF) to conduct phase-III trials of Russian vaccine Sputnik V and will distribute 10 crore doses of the anti-coronavirus vaccine, a press note released by RDIF said.

Pune-based Serum Institute of India and Hyderabad-based Biological-E are the two other Indian companies that have tied up with vaccine developers; Oxford-AstraZeneca and Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical companies of Johnson & Johnson, respectively, for domestic production of their vaccines.

The development at Dr. Reddy’s Lab comes a week after the Indian government publicly confirmed that it was in advanced talks with the Russians on two counts; production of the vaccine in India and conducting Phase-III clinical trials of the same in the country.

Russia’s federal government had approved emergency registration of the Sputnik V vaccine last month. The vaccine has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Moscow. The Russian government’s early approval for the vaccine, even before the commencement of the critical Phase-III trials, was met with skepticism and criticism from scientists around the world.

However, the partnership between Dr. Reddy’s and RDIF is an indication that the vaccine will have to go through the critical phase-III trials to test for efficacy and safety on a large number of people before it is approved by domestic regulators. Dr VK Paul, head of the National Covid-19 Task Force, had said last week that there would be phase-III trials in the normal course of things and that the government was also facilitating conduct of the trials, according to requirements of science and domestic regulations.

Dr. Reddy’s Lab co-chairman and managing mirector GV Prasad said, “We are pleased to partner with RDIF to bring the vaccine to India. Phase I and II results have shown promise, and we will be conducting phase-III trials in India to meet the requirements of Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India.”

The Sputnik V vaccine is based on the human adenoviral vector platform and phase-III trials are underway in Russia. “Deliveries could potentially begin in late 2020, subject to completion of successful trials and registration of the vaccine by regulatory authorities in India,” the RDIF press note stated.

“Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst the most severely impacted countries from COVID-19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID-19,” said RDIF CEO Kirill Dmitriev.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
 Share
Go to topic listing
×
×
  • Create New...